Nektar Financial Statements From 2010 to 2024

NKTR Stock  USD 0.93  0.04  4.49%   
Nektar Therapeutics financial statements provide useful quarterly and yearly information to potential Nektar Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Nektar Therapeutics financial statements helps investors assess Nektar Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nektar Therapeutics' valuation are summarized below:
Gross Profit
70.4 M
Market Capitalization
171.5 M
Enterprise Value Revenue
1.2051
Revenue
90.1 M
Earnings Share
(1.45)
There are over one hundred nineteen available fundamental ratios for Nektar Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to check Nektar Therapeutics' last-minute fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction.
Check Nektar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nektar main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.4 M, Interest Expense of 23.9 M or Total Revenue of 162.3 M, as well as many exotic indicators such as Price To Sales Ratio of 1.13, Dividend Yield of 0.001 or Operating Cycle of 170. Nektar financial statements analysis is a perfect complement when working with Nektar Therapeutics Valuation or Volatility modules.
  
This module can also supplement Nektar Therapeutics' financial leverage analysis and stock options assessment as well as various Nektar Therapeutics Technical models . Check out the analysis of Nektar Therapeutics Correlation against competitors.
To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.

Nektar Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets707.3 M398 M811.8 M
Slightly volatile
Short and Long Term Debt Total231 M230.4 M194.2 M
Slightly volatile
Other Current Liabilities27.8 M22.2 M32.2 M
Slightly volatile
Total Current Liabilities88.1 M51.3 M103.5 M
Very volatile
Property Plant And Equipment Net35 M36.9 M83 M
Slightly volatile
Accounts Payable8.3 M9.8 M7.7 M
Slightly volatile
Cash19.2 M20.2 M57.7 M
Pretty Stable
Non Current Assets Total64 M67.3 M240.6 M
Pretty Stable
Non Currrent Assets Other8.3 M4.6 MM
Slightly volatile
Cash And Short Term Investments437.9 M303.6 M513.4 M
Slightly volatile
Common Stock Shares Outstanding109 M190 M140.9 M
Slightly volatile
Liabilities And Stockholders Equity707.3 M398 M811.8 M
Slightly volatile
Non Current Liabilities Total301.7 M215.8 M302.7 M
Pretty Stable
Other Current Assets11.9 M8.7 M13.3 M
Slightly volatile
Other Stockholder Equity3.8 B3.6 B2.5 B
Slightly volatile
Total Liabilities389.8 M267 M406.2 M
Pretty Stable
Property Plant And Equipment Gross101.3 M123.8 M93.2 M
Slightly volatile
Total Current Assets476.4 M330.7 M560.1 M
Slightly volatile
Short Term Debt34.7 M19.3 M51.5 M
Pretty Stable
Current Deferred Revenue99.4 K104.7 K11.4 M
Slightly volatile
Common Stock Total Equity16.2 K17.1 KM
Slightly volatile
Short Term Investments407.6 M283.5 M460.6 M
Slightly volatile
Common Stock16.2 K17.1 KM
Slightly volatile
Net Receivables2.1 M2.3 M14 M
Pretty Stable
Other Liabilities105.7 M187.4 M135.7 M
Slightly volatile
Other Assets2.5 M2.6 M25 M
Very volatile
Long Term Debt200.4 M222.3 M206.5 M
Slightly volatile
Property Plant Equipment77.9 M77.3 M78.3 M
Pretty Stable
Inventory13.3 M16.1 M13.2 M
Slightly volatile
Intangible Assets23 M24.2 M58.1 M
Slightly volatile
Long Term Debt Total191.7 M284 M191.5 M
Slightly volatile
Capital Surpluse2.6 BB2.5 B
Slightly volatile
Capital Lease Obligations74 M117.8 M75.9 M
Slightly volatile
Deferred Long Term Liabilities16.3 M17.1 M49.5 M
Slightly volatile
Non Current Liabilities Other150.7 M117.3 M129.3 M
Slightly volatile
Short and Long Term Debt246.1 M286 M212 M
Slightly volatile
Net Invested Capital124.4 M131 M577.5 M
Pretty Stable
Net Working Capital265.5 M279.4 M489.6 M
Slightly volatile
Capital Stock20 K21.9 K17.9 K
Slightly volatile

Nektar Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue162.3 M90.1 M207.7 M
Very volatile
Gross Profit50.8 M53.5 M176.1 M
Very volatile
Other Operating Expenses258 M227.5 M317.2 M
Slightly volatile
Total Operating Expenses228.8 M190.9 M291.1 M
Slightly volatile
Research Development184.5 M111.3 M229 M
Slightly volatile
Selling General Administrative52.5 M77.4 M62.9 M
Slightly volatile
Non Recurring13.6 M18.4 M13.1 M
Slightly volatile
Tax Provision3.1 MM1.1 M
Slightly volatile
Interest Income15.4 M17.6 M25 M
Slightly volatile
Reconciled Depreciation10.2 M9.3 M13.5 M
Slightly volatile
Selling And Marketing Expenses1.8 MM2.2 M
Slightly volatile

Nektar Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow66.9 M66.8 M58.7 M
Slightly volatile
Depreciation7.4 M7.8 M12 M
Very volatile
Capital Expenditures821.8 K865 K8.9 M
Very volatile
End Period Cash Flow19.2 M20.2 M57.7 M
Pretty Stable
Stock Based Compensation31 M33.4 M43.4 M
Slightly volatile
Sale Purchase Of Stock36.3 M38.2 M116.2 M
Very volatile
Change To Netincome50.1 M58.3 M45 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.131.191214.0532
Pretty Stable
Dividend Yield0.0010.0010.0011
Slightly volatile
Operating Cycle170169229
Pretty Stable
Inventory Turnover3.212.27592.1088
Very volatile
Ebt Per Ebit2.112.01021.5665
Pretty Stable
Long Term Debt To Capitalization0.420.46230.5839
Pretty Stable
Cash Per Share3.151.5983.2483
Slightly volatile
Total Debt To Capitalization0.410.50170.5671
Slightly volatile
Quick Ratio4.865.96596.1268
Slightly volatile
Net Income Per E B T0.740.99930.9881
Slightly volatile
Cash Ratio0.370.39321.1339
Slightly volatile
Days Of Inventory Outstanding141160194
Very volatile
Days Of Sales Outstanding8.669.120733.0808
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.281.00451.0963
Slightly volatile
Current Ratio7.326.45036.8423
Slightly volatile
Fixed Asset Turnover1.782.44483.4523
Very volatile
Debt Ratio0.270.33130.2882
Pretty Stable
Price Sales Ratio1.131.191214.0532
Pretty Stable
Receivables Turnover42.0240.018726.3055
Very volatile
Asset Turnover0.180.22640.2581
Pretty Stable
Gross Profit Margin0.90.59340.8308
Pretty Stable

Nektar Fundamental Market Drivers

Cash And Short Term Investments303.6 M

Nektar Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Nektar Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Nektar Therapeutics income statement, its balance sheet, and the statement of cash flows. Nektar Therapeutics investors use historical funamental indicators, such as Nektar Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Nektar Therapeutics investors may use each financial statement separately, they are all related. The changes in Nektar Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Nektar Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Nektar Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Nektar Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue104.7 K99.4 K
Total Revenue90.1 M162.3 M
Cost Of Revenue36.6 M26.8 M
Ebit Per Revenue(1.52)(1.60)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Nektar Therapeutics is a strong investment it is important to analyze Nektar Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nektar Therapeutics' future performance. For an informed investment choice regarding Nektar Stock, refer to the following important reports:
Check out the analysis of Nektar Therapeutics Correlation against competitors.
To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for Nektar Stock analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
CEOs Directory
Screen CEOs from public companies around the world
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Is Nektar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nektar Therapeutics. If investors know Nektar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nektar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.45)
Revenue Per Share
0.474
Quarterly Revenue Growth
0.085
Return On Assets
(0.15)
Return On Equity
(1.11)
The market value of Nektar Therapeutics is measured differently than its book value, which is the value of Nektar that is recorded on the company's balance sheet. Investors also form their own opinion of Nektar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nektar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nektar Therapeutics' market value can be influenced by many factors that don't directly affect Nektar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nektar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nektar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nektar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.